Veracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company's commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: VCYT
- Previous Close: $8.00
- 50 Day Moving Average: $7.61
- 200 Day Moving Average: $7.04
- 52-Week Range: $4.21 - $8.48
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.60
- P/E Growth: 0.00
- Market Cap: $223.60M
- Outstanding Shares: 27,950,000
- Beta: 2
- Net Margins: -57.45%
- Return on Equity: -88.36%
- Return on Assets: -46.01%
Companies Related to Veracyte:
- Debt-to-Equity Ratio: 0.83%
- Current Ratio: 4.18%
- Quick Ratio: 3.85%
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
Where is Veracyte's stock going? Where will Veracyte's stock price be in 2017?
6 equities research analysts have issued 1-year target prices for Veracyte's shares. Their forecasts range from $10.00 to $13.00. On average, they anticipate Veracyte's share price to reach $11.25 in the next twelve months.
When will Veracyte announce their earnings?
Veracyte is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
What are analysts saying about Veracyte stock?
Here are some recent quotes from research analysts about Veracyte stock:
According to Zacks Investment Research, "Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California. " (1/25/2017)
Leerink Swann analysts commented, "We reiterate our OP rating and maintain our PT of $12. Commercial Payers Still Key to Driving Adoption Ramp and Sales Longer-term. VCYT has successfully driven the Afirma adoption ramp by gaining multi-year commercial payer contracts on the back of solid clinical evidence — as 80% of Afirma volumes still comes from private payers. Afirma currently has 185M lives covered and $155M contracted with 25M of those lives in Blue Cross Blue Shield. Beyond that, for Afirma GEC, VCYT’s key priorities include securing a positive coverage decision for the largest Blues payer: Anthem (ANTM, OP) with its 40M covered lives, and converting other Blues payers to in-network contracts. Medicare accounts for only 20% of Afirma test samples and thus the eliminated impact was only ~$1.6M. Plus, with the new data that was released at the ATA meeting recently highlighting 70%-80% of specificity of the enhanced Afirma test, we believe VCYT should be able to get Anthem as well." (11/22/2016)
Who owns Veracyte stock?
Veracyte's stock is owned by many different of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (8.06%), Broadfin Capital LLC (6.40%), Stonepine Capital Management LLC (3.47%), First Light Asset Management LLC (2.48%), Federated Investors Inc. PA (1.88%) and Axiom International Investors LLC DE (1.03%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Shelly D Guyer.
Who sold Veracyte stock? Who is selling Veracyte stock?
Veracyte's stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates.
Who bought Veracyte stock? Who is buying Veracyte stock?
Veracyte's stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Stonepine Capital Management LLC, Axiom International Investors LLC DE, First Light Asset Management LLC, Oxford Asset Management, Denver Investment Advisors LLC, ARK Investment Management LLC and Birchview Capital LP.
How do I buy Veracyte stock?
Shares of Veracyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Veracyte stock cost?
One share of Veracyte stock can currently be purchased for approximately $8.00.